AG-120 (Ivosidenib)是一种突变型异柠檬酸脱氢酶1（mIDH1）抑制剂。
Cas No.:1448347-49-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
AG-120 (Ivosidenib) is an inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1)[1-2]. AG-120 reduces the levels of the oncogenic metabolite 2-hydroxyglutarate (2-HG) by inhibiting the mutant IDH1 enzyme. AG-120 is used in research related to IDH1-mutant acute myeloid leukemia and cholangiocarcinoma[3-4].
In vitro, AG-120 (0-100nM) was used to treat IDH1-mutant RBE cells, alone or in combination with an HNF4α-overexpressing adenovirus (AdHNF4α) for 3-30 days. AG-120 inhibited cell viability, and the combination treatment significantly enhanced the inhibitory effect on tumor growth[5]. AG-120 (1µM) was combined with gemcitabine (GEM; 10nM) to treat GEM-resistant HuCCT1 and other iCCA cells expressing wild-type IDH1 under low magnesium conditions for 10 days. This combination significantly inhibited cell proliferation, increased intracellular oxidative stress, and decreased the GSH/GSSG ratio[6].
In vivo, AG-120 (75mg/kg; p.o.; twice daily) was administered in combination with 5-FU (30mg/kg; i.p.; twice weekly) for 37 days to nude mice bearing PDX (TM01212) or Mia-Paca2 xenograft tumors. AG-120 significantly inhibited tumor growth and enhanced the antitumor efficacy of the chemotherapeutic agent[7]. AG-120 (150mg/kg; p.o.; once daily) was administered for 28 days to nude mice bearing ICC-9810 cell-derived or patient-derived xenograft tumors. AG-120 significantly suppressed tumor growth and reduced the protein levels of IDH1, NRF2, and HO-1 in the tumor tissues[8].
References:
[1] Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. ACS Med Chem Lett. 2018 Jan 19;9(4):300-305.
[2] Montesinos P, Recher C, Vives S, et al. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. N Engl J Med. 2022 Apr 21;386(16):1519-1531.
[3] Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Jun;21(6):796-807.
[4] Mellinghoff IK, Ellingson BM, Touat M, et al. Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. J Clin Oncol. 2020 Oct 10;38(29):3398-3406.
[5] Xu BN, Ding CH, Liu YL, et al. HNF4α inhibits the malignancy of intrahepatic cholangiocarcinoma by suppressing the Wnt signaling pathway. Transl Oncol. 2025 Mar;53:102290.
[6] Li X, Song Z, Lin S, et al. The allosteric IDH1 inhibitor ivosidenib overcomes chemoresistance in intrahepatic cholangiocarcinoma models expressing wild-type IDH1. J Clin Invest. 2026 Mar 17:e199730.
[7] Zarei M, Hajihassani O, Hue JJ, et al. IDH1 Inhibition Potentiates Chemotherapy Efficacy in Pancreatic Cancer. Cancer Res. 2024 Sep 16;84(18):3072-3085.
[8] Hao Z, Yang H, Zhu W, et al. ALYREF Promotes Progression of Intrahepatic Cholangiocarcinoma through Increasing the Level of Isocitrate Dehydrogenase 1 in an m5C-Dependent Manner. Mol Cell Biol. 2025;45(5):198-211.
AG-120 (Ivosidenib)是一种突变型异柠檬酸脱氢酶1（mIDH1）抑制剂[1-2]。AG-120通过抑制突变型IDH1酶来降低致癌代谢物2-羟基戊二酸（2-HG）的水平。AG-120可用于IDH1突变的急性髓系白血病和胆管癌的相关研究[3-4]。
在体外，AG-120（0-100nM）单独或与HNF4α过表达腺病毒（AdHNF4α）联合处理携带IDH1突变的RBE细胞3-30天。AG-120可抑制细胞活力，并在联合处理时显著增强对肿瘤生长的抑制作用[5]。AG-120（1μM）与吉西他滨（GEM；10nM）在低镁条件下联合处理表达野生型IDH1的GEM耐药HuCCT1等iCCA细胞10天。AG-120可显著抑制细胞增殖，同时增加细胞内氧化应激、降低GSH/GSSG比值[6]。
在体内，AG-120（Ivosidenib）（75mg/kg；口服；每天两次）联合5-FU（30mg/kg；腹腔注射；每周两次）处理携带PDX（TM01212）或Mia-Paca2异种移植瘤的裸37天。AG-120显著抑制了肿瘤生长，并增强了化疗药物的抗肿瘤功效[7]。AG-120（150mg/kg；口服；每天一次）处理携带ICC-9810细胞或病人来源肿瘤组织异种移植的裸28天。AG-120显著抑制了肿瘤生长，并降低了肿瘤组织中IDH1、NRF2和HO-1的蛋白水平[8]。
| Cell experiment [1]: | |
Cell lines | HuCCT1 cells (a human intrahepatic cholangiocarcinoma cell line with primary resistance to gemcitabine) |
Preparation Method | HuCCT1 cells expressing wild-type IDH1 were cultured under low magnesium conditions. The cells were pretreated with AG-120 (1μM) and subsequently co-treated with gemcitabine. |
Reaction Conditions | 1μM; 10 days. |
Applications | AG-120 significantly enhanced the anti-proliferative effect of gemcitabine, increased intracellular oxidative stress, and decreased the glutathione redox ratio (GSH/GSSG) and α-ketoglutarate (αKG) content. AG-120 treatment also reduced the de novo synthesis of TCA cycle-related 13C-enriched metabolites, indicating an attenuation of mitochondrial metabolic flux. |
| Animal experiment [2]: | |
Animal models | BALB/c nude mice bearing ICC-9810 cell-derived or patient-derived xenograft tumors |
Preparation Method | Xenograft tumor models were established by subcutaneous injection of ICC-9810 cells or patient tumor tissue homogenates. Mice in the AG-120 (150mg/kg) group received the drug by oral gavage. |
Dosage form | 150mg/kg; p.o.; once per day for 28 days. |
Applications | AG-120 administration significantly suppressed tumor growth in vivo. AG-120 also significantly reduced the protein levels of IDH1, NRF2, and HO-1 in the harvested tumor tissues. |
References: | |
| Cas No. | 1448347-49-6 | SDF | |
| 别名 | 艾伏尼布,AG-120 | ||
| 化学名 | (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide | ||
| Canonical SMILES | O=C([C@H](CC1)N(C2=NC=CC(C#N)=C2)C1=O)N([C@@H](C3=CC=CC=C3Cl)C(NC4CC(F)(F)C4)=O)C5=CC(F)=CN=C5 | ||
| 分子式 | C28H22ClF3N6O3 | 分子量 | 582.96 |
| 溶解度 | ≥ 58.3mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7154 mL | 8.5769 mL | 17.1538 mL |
| 5 mM | 343.1 μL | 1.7154 mL | 3.4308 mL |
| 10 mM | 171.5 μL | 857.7 μL | 1.7154 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet